iNeedMD Holdings Inc
Change company Symbol lookup
Select an option...
NEMD iNeedMD Holdings Inc
CVS CVS Health Corp
CMI Cummins Inc
INVH Invitation Homes Inc
OII Oceaneering International Inc
SINO Sino-Global Shipping America Ltd
MLM Martin Marietta Materials Inc
KO Coca-Cola Co
VICI VICI Properties Inc
PLT Plantronics Inc
Go

Company profile

iNeedMD Holdings, Inc. is a medical device company that has developed a disposable device used in the diagnosis, prevention, and monitoring of cardiovascular disease. The Company develops and markets medical device solutions that enable individuals and their healthcare partners to acquire, store and export health- and wellness-related data in portable platforms. Its product development programs focus on systems for collecting a plurality of diagnostic information and transmitting that data to local and/or remote locations. Its products include The EKG Glove and Portable ECG devices. The EKG Glove is a medical device that facilitates a 12-lead electrocardiogram (ECG) at rest using embedded, printed circuitry connected to pre-positioned electrodes. The Portable ECG devices communicate with Windows-based tablets, laptops, or personal computers via Bluetooth or Universal Serial Bus (USB). It performs, stores and shares ECG reports locally or provides remote access.

Closing Price
$0.20
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
400
0

Shares of Inovio rise 6% on vaccine manufacturing deal with Thermo Fisher

8:27 am ET September 8, 2020 (MarketWatch)
Print

Shares of Inovio Pharmaceuticals Inc. (INO) gained 6.5% in premarket trading on Tuesday after the company said it had added Thermo Fisher Scientific (TMO) as a manufacturing partner for its COVID-19 vaccine candidate. Thermo's stock was down 0.2%. Inovio has announced a number of manufacturing partners to help it meet its target of making 100 million doses of the still investigational vaccine candidate in 2021. Thermo has been tasked with manufacturing drug substance and doing fill-and-finish work for the vaccine. Inovio has released limited data from its Phase 1 clinical trial, with plans to publish the full data in a peer-reviewed medical journal, and said it expects to start its Phase 2/3 trial this month, once it gets the go-ahead from the Food and Drug Administration. Inovio's stock has rallied 190.0% this year, while the S&P 500 is up 6.0%.

-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

September 08, 2020 08:27 ET (12:27 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.